Edition:
United States

Sarepta Therapeutics Inc (SRPT.O)

SRPT.O on Nasdaq

124.95USD
16 Aug 2019
Change (% chg)

$2.98 (+2.44%)
Prev Close
$121.97
Open
$123.35
Day's High
$126.19
Day's Low
$123.12
Volume
1,239,233
Avg. Vol
1,170,807
52-wk High
$165.87
52-wk Low
$95.21

About

Sarepta Therapeutics, Inc. is a biopharmaceutical company. The Company focuses on the discovery and development of ribose nucleic acid (RNA)-targeted therapeutics for the treatment of rare neuromuscular diseases. It operates through discovering, developing, manufacturing and delivering therapies to patients with Duchenne... (more)

Overall

Beta: 1.28
Market Cap(Mil.): $3,262.29
Shares Outstanding(Mil.): 64.33
Dividend: --
Yield (%): --

Financials

  SRPT.O Industry Sector
P/E (TTM): -- 69.38 32.67
EPS (TTM): -2.44 -- --
ROI: -47.63 8.94 14.48
ROE: -49.74 10.07 15.78

Sarepta says adverse event report for DMD gene therapy erroneously submitted

Sarepta Therapeutics Inc said on Thursday it was informed that an adverse event report was erroneously submitted to the U.S. health regulator regarding an ongoing study of the company's gene therapy for Duchenne muscular dystrophy (DMD).

Aug 08 2019

UPDATE 1-Patient in Sarepta gene therapy trial develops serious illness; shares plunge

Aug 8 Shares of Sarepta Therapeutics Inc plunged 12% after a notice from the U.S. health agency showed a patient in an ongoing study of the company's gene therapy for Duchenne muscular dystrophy (DMD) was reported to have developed a serious illness.

Aug 08 2019

Patient in Sarepta gene therapy trial develops serious illness; shares plunge

Aug 8 Shares of Sarepta Therapeutics Inc plunged 12% after a notice from the U.S. health agency showed a patient in an ongoing study of the company's gene therapy for Duchenne muscular dystrophy was reported to have developed a serious illness.

Aug 08 2019

Sarepta surges after Pfizer gene therapy data raises safety concerns

Shares of Sarepta Therapeutics Inc surged 15% on Friday after some safety concerns were raised in a small, early-stage study of a competing gene therapy for a rare muscle-wasting disorder from Pfizer Inc .

Jun 28 2019

UPDATE 2-Sarepta surges after Pfizer gene therapy data raises safety concerns

June 28 Shares of Sarepta Therapeutics Inc surged 15% on Friday after some safety concerns were raised in a small, early-stage study of a competing gene therapy for a rare muscle-wasting disorder from Pfizer Inc.

Jun 28 2019

Sarepta shares rise after gene therapy deal, promising data

Sarepta Therapeutics Inc beefed up its gene therapies portfolio through the purchase of its partner Myonexus Therapeutics Inc and reported positive data for a genetic disorder therapy from the privately held company, sending its shares up 9 percent on Wednesday.

Feb 27 2019

UPDATE 1-Sarepta to buy Myonexus for $165 mln in gene therapy push

Feb 27 Sarepta Therapeutics Inc said on Wednesday it would buy privately held gene therapy company Myonexus Therapeutics Inc for $165 million, moving deeper into an emerging and lucrative field within the biotech sector.

Feb 27 2019

Sarepta to buy gene therapy developer Myonexus for $165 mln

Feb 27 Sarepta Therapeutics Inc said on Wednesday it exercised its option to buy privately held gene therapy maker Myonexus Therapeutics Inc for $165 million.

Feb 27 2019
Reuters.com is improving our Quote page. Click here to take a look and let us know what you think.

Earnings vs. Estimates